GFM
ACRS icon

GF Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

GF Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.07K Buy
2,419
+291
+14% +$982 ﹤0.01% 568
2025
Q4 		$6.41K Buy
+2,128
New +$5.38K ﹤0.01% 607

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GF Fund Management's ACRS Position: Q1 2026 in Review

GF Fund Management increased its Aclaris Therapeutics (ACRS) stake by 14% in Q1 2026, buying an estimated $982 and bringing the position to 2,419 shares worth $9.07K. The position accounts for ﹤0.01% of the portfolio, ranked #568.

GF Fund Management first reported a position in ACRS in Q4 2025 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • GF Fund Management held 2,419 shares of Aclaris Therapeutics worth $9.07K as of Q1 2026.
  • GF Fund Management bought 291 Aclaris Therapeutics shares in Q1 2026, an estimated $982.
  • Aclaris Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #568 holding.
  • GF Fund Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.